Clinical Evidence of Combining Radiopharmaceutical Therapy With Immune Checkpoint Inhibitors
Introduction
Radiopharmaceutical therapy (RPT) and immune checkpoint inhibitors (ICIs) represent transformative approaches to treating metastatic cancers. This review article discusses how RPT delivers targeted radiation to primary and metastatic tumors and the therapeutic advantages of combining RPT with ICIs while focusing on outcomes and challenges such as toxicity, immunosuppressive tumor microenvironment, and logistical barriers.
Learning Objectives
Upon completing this activity, the reader should be able to:
-
Distinguish the physical properties of α, β, and Auger-emitting radioisotopes to guide informed selection of radionuclides for RPT based on therapeutic goals and tumor characteristics.
-
Evaluate clinical trial data on RPT-ICI combinations and integrate evidence-based insights into patient selection, dosing strategies, and treatment sequencing for optimized therapeutic outcomes.
Authors
Malick Bio Idrissou, PhD;1 Anusha Muralidhar;2 Reinier Hernandez;1,3,4 Quaovi H. Sodji4,5,6*
Affiliations:1 Department of Medical Physics, University of Wisconsin-Madison, Madison, WI;2 Department of Cancer Biology, University of Wisconsin-Madison, Madison, WI ;3 Department of Radiology, University of Wisconsin-Madison, Madison, WI;4 Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI;5 Department of Human Oncology, University of Wisconsin-Madison, Madison, WI;6 William S. Middleton Memorial Veterans Hospital, Madison, WI.
Target Audience
-
Radiologists
-
Related imaging professionals
Commercial Support
None
Accreditation/Designation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Advanced Medical Education (IAME) and Anderson Publishing. IAME is accredited by the ACCME to provide continuing medical education for physicians. IAME designates this activity for a maximum of 1 AMA PRA Category 1 Credit™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions
-
Review this article in its entirety.
-
Visit appliedradiology.org/SAM2.
-
Login or create an account.
-
Complete the post test and review the discussion and references.
-
Complete the evaluation.
-
Print your certificate.
Estimated Time for Completion
1 hour
Date of Release and Review
4/1/2025
Expiration Date
3/31/2026
Disclosures
The authors disclose no relationships with ineligible companies.
IAME has assessed conflicts of interest with its faculty, authors, editors, and any individuals who were in a position to control the content of this CME activity. Any relevant financial relationships were mitigated with an independent peer review of this activity, and no conflicts or commercial bias were detected. IAME’s planners, content reviewers, and editorial staff disclose no relationships with ineligible entities.
References
Citation
. Clinical Evidence of Combining Radiopharmaceutical Therapy With Immune Checkpoint Inhibitors. Appl Radiat Oncol. 2025;(1):1 - 1.
doi:10.37549/ARO-D-24-00039CME
March 1, 2025